Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer

Fig. 6

Immunofluorescence analysis on orthotopic syngeneic PDAC mouse model. a Multiplex IF analysis showing the correlation of PanCK, GCNT3, MUC1, MUC5AC in KPC06 mice models randomly assigned to receive saline (CTR), standard therapy (Gem/Txl), talniflumate (TALN) and talniflumate-Gem/Txl combination treatment (COMB). Images shown are representative of 1 out of more than 10 fields acquired and reviewed by pathologist. b IF showing the expression of CD8, CD68, iNOS, and CD163 in the same experimental groups. Images shown are representative of 1 out of more than 10 fields acquired and reviewed by pathologist. c Barplots show percentage of positive cells per area grouped by treatments. Kruskal–Wallis test was used to compare differences between treatments and control. **** = Pvalue < 0.0001, *** = Pvalue < 0.001, *** = Pvalue < 0.01,* = Pvalue < 0.05

Back to article page